Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc (HOLX) delivers innovative healthcare solutions through diagnostic imaging systems and surgical technologies focused on women’s health. This dedicated news hub provides investors and industry professionals with essential updates directly from the company and verified sources.
Access timely Hologic press releases, earnings reports, and strategic announcements in one centralized location. Track developments across key business segments including diagnostic systems, breast health technologies, and minimally invasive surgical solutions. Our curated feed ensures you never miss regulatory filings, product approvals, or partnership announcements impacting this medical technology leader.
This resource serves as your primary source for monitoring Hologic’s advancements in healthcare diagnostics and operational milestones. Content is rigorously verified to maintain factual accuracy while avoiding speculative analysis. Bookmark this page for efficient tracking of HOLX’s progress in developing technologies that enhance clinical decision-making worldwide.
Four new studies about the Breast Cancer Index (BCI) test will be presented at the 2024 San Antonio Breast Cancer Symposium. The main study investigates BCI's potential to identify postmenopausal women with HR+ early-stage breast cancer who have minimal risk of distant recurrence.
The research validated an adjusted BCI prognostic model that identified a 'minimal risk' group with less than 5% 10-year distant recurrence risk. In the Stockholm and NCR studies, 20% and 16% of patients were identified as minimal risk, with 10-year distant recurrence risks of 2.3% and 4.5%, respectively.
The BCI test is currently recognized by NCCN and ASCO guidelines as the only test predicting which HR+ early-stage breast cancer patients may benefit from extended endocrine therapy beyond five years.
Hologic (NASDAQ: HOLX) presented new research demonstrating its Genius AI Detection 2.0 software performs consistently across diverse patient populations. The study evaluated over 7,500 digital breast tomosynthesis cases from women of different racial/ethnic backgrounds, showing similar performance across all groups. The company also announced the introduction of its next-generation Genius AI Detection PRO solution for the U.S. market, featuring improved accuracy, efficiency, and advanced capabilities including deep-learning algorithms, intuitive scoring, and an all-in-one interface with breast density scoring.
Hologic (NASDAQ: HOLX) will showcase new breast health technologies at RSNA 2024 in Chicago, December 1-5. The company will unveil the Envision™ Mammography Platform, featuring a 2.5-second scan time and tilt positioning for enhanced patient comfort. Additionally, Hologic will introduce its Genius AI® Detection PRO solution, an advanced cancer screening technology that improves accuracy and efficiency through deep-learning algorithms.
The company will present study results showing their AI Detection 2.0 software performs consistently across diverse patient populations. At Booth #1919, Hologic will display their complete portfolio of breast imaging and surgery solutions, including recently acquired Endomag wireless breast surgery localization products.
Hologic (HOLX) has announced its participation in three upcoming investor conferences. The company will present at the 2024 Stephens Annual Investment Conference in Nashville on November 21st at 10 a.m. CT, the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables on December 3rd at 2:10 p.m. ET, and Citi's 2024 Global Healthcare Conference in Miami on December 4th at 8:45 a.m. ET. All presentations will be accessible via webcast through Hologic's investor relations website for 30 days following each event.
Hologic (HOLX) reported strong Q4 2024 financial results with revenue of $987.9 million, up 4.5% year-over-year. The company achieved GAAP EPS of $0.76 and Non-GAAP EPS of $1.01. Organic revenue excluding COVID-19 grew 5.0% in constant currency. Key segment performance included Diagnostics revenue increasing 6.5%, Breast Health revenue rising 6.4%, and Surgical revenue growing 5.7%. The company maintained strong cash flow from operations at $367.1 million and announced plans for a $250 million accelerated share repurchase program. Hologic completed the acquisition of Endomagnetics for $310 million and announced an agreement to acquire Gynesonics for approximately $350 million.
Hologic, Inc. (Nasdaq: HOLX), a global women's health champion, has announced a definitive agreement to acquire Gynesonics, Inc., a private medical device company, for approximately $350 million. Gynesonics develops the Sonata® System, a minimally invasive technology for diagnosing and treating symptomatic uterine fibroids, including those causing heavy menstrual bleeding. The system combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure.
Brandon Schnittker, Division President of Surgical Solutions at Hologic, stated that the acquisition will expand options for GYN surgeons globally to treat women with heavy periods and fibroids. The deal aligns with Hologic's commitment to providing minimally invasive treatment options and enhancing women's quality of life. The acquisition's completion is subject to customary closing conditions and regulatory approvals.
Hologic (Nasdaq: HOLX) has announced plans to release its financial results for the fourth quarter of fiscal 2024 on Monday, November 4, after market close. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results.
Interested participants can join the call by dialing (888) 394-8218 (US and Canada) or +1 (773) 305-6853 (international) with access code 4567924. A live webcast and replay will be available on Hologic's investor relations website for 30 days. The webcast replay will be accessible approximately two hours after the call ends.
Hologic is an innovative medical technology company primarily focused on improving women's health through early detection and treatment.
Hologic (Nasdaq: HOLX) launches the #BustTheMyth campaign for Breast Cancer Awareness Month, aiming to debunk common misconceptions about breast cancer, mammograms, and breast density. The company will ring the Nasdaq opening bell for the 18th year to kick off this initiative.
The campaign addresses key myths, such as the misconception that only those with a family history need mammograms, when in fact 85% of women diagnosed have no family history. It also emphasizes that breast density, a risk factor for breast cancer, can only be determined by mammograms.
Hologic's effort comes at a important time, following updated breast cancer screening guidelines and new FDA reporting standards on breast density. The company's 3D Mammography™ exam is FDA-approved as superior for women with dense breasts compared to 2D alone.
Despite breast cancer being highly treatable when detected early, over 40% of U.S. women report skipping screenings. Hologic aims to empower women with facts to prioritize their health and encourage annual screenings.
Hologic (Nasdaq: HOLX), a leading medical technology company focused on women's health, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place on September 5th at 12:20 p.m. Eastern Time in New York.
The company will engage in a fire-side chat presentation, which will be webcast live and accessible through the investors section of Hologic's website. The webcast will remain available for 30 days following the event, providing an opportunity for investors and interested parties to gain insights into Hologic's latest developments and strategies.
This presentation at a major healthcare conference underscores Hologic's commitment to transparency and engagement with the investment community, potentially impacting investor perceptions and the company's stock performance.
Hologic (NASDAQ: HOLX) reported strong financial results for Q3 fiscal 2024, with revenue of $1,011.4 million, up 2.7% year-over-year. GAAP EPS was $0.82, and non-GAAP EPS was $1.06, both exceeding guidance. Organic revenue excluding COVID-19 grew 5.8% in constant currency. Key highlights include:
- Diagnostics revenue increased 0.3%, with Molecular Diagnostics up 2.8%
- Breast Health revenue rose 6.9%, driven by strong gantry sales and service
- Surgical revenue grew 5.9%
- Cash flow from operations was $405.7 million
- The company repurchased 1.4 million shares for $100 million
Hologic raised its full-year 2024 revenue guidance to $4,012 - $4,027 million and non-GAAP EPS guidance to $4.04 - $4.11. The company's strong performance demonstrates the durability of its broad portfolio across Diagnostics, Breast Health, and Surgical franchises.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
